Mark Lerohl is listed as a director on 1 SEC Form D filing by 1 issuer in Dec 2019: Luna Pharmaceuticals, Inc. (Providence, RI — other health care — 2019; $2.26M reported sold to 21 investors).
What this means One deal on file with the SEC, filed Dec 2019. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Amy Wolf (1 shared filing), Dan Aziz (1 shared filing), Kevin Murphy (1 shared filing), Raymond Mathieu (1 shared filing) and Richard Katzman (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Mark. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 2 bankruptcy cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Mark Lerohl and found 3 differences: Mark Lerohl appears on 1 deal that stopped filing before reaching its target; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.